Holen Sie sich die Stockscreener-App
192.42
0.48%
0.92
Vorhandelsmarkt:
191.00
-1.42
-0.74%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$191.50
Offen:
$192.2
24-Stunden-Volumen:
5.78M
Relative Volume:
0.77
Marktkapitalisierung:
$331.15B
Einnahmen:
$57.37B
Nettoeinkommen (Verlust:
$4.20B
KGV:
81.88
EPS:
2.35
Netto-Cashflow:
$15.39B
1W Leistung:
+2.64%
1M Leistung:
+1.24%
6M Leistung:
+11.10%
1J Leistung:
+15.85%
1-Tages-Spanne:
$187.41
$193.59
1-Wochen-Bereich:
$187.41
$193.59
52-Wochen-Spanne:
$163.52
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
192.42 | 331.15B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
812.03 | 687.38B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.66 | 369.72B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
81.05 | 322.81B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
120.77 | 232.65B | 53.22B | 12.86B | 14.85B | 6.39 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
FDA approves label expansion of AbbVie’s HCV therapy - Pharmaceutical Technology
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - MSN
Kalkine: Can FDA Approval Reshape AbbVie’s Role In S&P 500 - Kalkine Media
Giant-Cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight - GlobeNewswire
Giant-Cell Arteritis Market Heats up with AbbVie’s RINVOQ Approval | DelveInsight - GlobeNewswire Inc.
AbbVie (ABBV) Secures FDA Approval for Expanded Use of Mavyret - GuruFocus
AbbVie (ABBV) Gains As Market Dips: What You Should Know - Yahoo Finance
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection - AOL.com
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
Endometriosis Market on Track for Major Expansion by 2034, - openPR.com
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Gle - GuruFocus
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® as First and Only Treatment for People with Acute Hepatitis C Virus - Investing News Network
AbbVie announces FDA approval for MAVYRET expanded indication - TipRanks
AbbVie Receives FDA Label Expansion Approval for Mavyret to Treat Hepatitis C - marketscreener.com
AbbVie's (ABBV) MAVYRET Gains FDA Approval for Expanded Hepatitis C Treatment | ABBV Stock News - GuruFocus
FDA Grants Historic Approval: New 8-Week Hepatitis C Treatment Achieves Breakthrough 96% Cure Rate - Stock Titan
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus - Longview News-Journal
Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart - insights.citeline.com
AbbVie at Goldman Sachs Conference: Strategic Growth and Innovation - Investing.com
Transcript : AbbVie Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE? - The Globe and Mail
AbbVie Stock Dips Slightly, Pausing a Consistent and Powerful Bull Run - Daily Chhattisgarh News
AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology with Temab-A ABBV-706 & PVEK - Pharmaphorum
AbbVie's Emrelis approval marks milestone for long-ago Bay Area biotech buyout - The Business Journals
AbbVie Inc. (NYSE:ABBV) Q1 2025 Earnings Call Transcript - MSN
AbbVie (ABBV) Stocks Surge with Promising Outlook - GuruFocus
AbbVie continues gains for seven straight sessions - MSN
AbbVie continues gains for seven straight sessions (ABBV:NYSE) - Seeking Alpha
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise? - The Globe and Mail
Two Sigma Investments LP Sells 1,700 Shares of AbbVie Inc. (NYSE:ABBV) - Defense World
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
AbbVie (ABBV): Buy, Sell, or Hold Post Q1 Earnings? - FinancialContent
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV) - TradingView
Alzheimers Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
ABBV: Bullish Momentum Evident in AbbVie Options Activity | ABBV Stock News - GuruFocus
AbbVie call volume above normal and directionally bullish - TipRanks
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons - Yahoo Finance
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Investing News Network
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award Contest to Support Their Professional Goals - Investing News Network
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals | ABBV Stock News - GuruFocus
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | ABBV Stock News - GuruFocus
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals - Longview News-Journal
Immunology Market Deep Research Report Signals Rapid GrowthAbbVie Inc., Johnson & Johnson - openPR.com
How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks? - MSN
AbbVie Inc. (ABBV) and Chicago Cubs Launch “Striking Out Cancer” Campaign - Insider Monkey
AbbVie announces multi-year partnership with the Chicago Cubs - TipRanks
Final Trades: JPMorgan, Meta, Abbvie and Gap - CNBC
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness Initiative | ABBV Stock News - GuruFocus
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):